Both the conception of the study by the investigators and its subsequent selection by the Glaser Pediatric Research Network in 2001 were driven by the publication of a series of small, uncontrolled trials of metformin in obesity and/or insulin-resistant adolescents. We agree that lifestyle inventions for obese adolescents are important and thus designed our trial such that both metformin and placebo groups received the identical lifestyle intervention.
Wilson DM. Analysis of Metformin Treatment for Adolescent Obesity at 48 Rather Than 24 Weeks After Treatment Cessation—Reply. Arch Pediatr Adolesc Med. 2010;164(7):678-679. doi:10.1001/archpediatrics.2010.111